Article
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial.
Lung cancer (Amsterdam, Netherlands) - 1 Apr 2023
Lv Chao, Fang Wentao, Wu Nan, Jiao Wenjie, Xu Shidong, Ma Haitao, Wang Jia, Wang Rui, Ji Chunyu, Li Shaolei, Wang Yuzhao, Yan Shi, Lu Fangliang, Pei Yuquan, Liu Yinan, Yang Yue
Abstract excerpt
OBJECTIVES: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been approved for EGFR-mutant non-small-cell lung cancer (NSCLC). We aimed to evaluate the efficacy and safety of neoadjuvant osimertinib in patients with EGFR-mutant resectable locally advanced NSCLC. MATERIALS AND METHODS: This single-arm, phase 2b trial (ChiCTR1800016948) was conducted at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.